
Tara L. Martinez
Examiner (ID: 11490, Phone: (571)270-1470 , Office: P/1675 )
| Most Active Art Unit | 1654 |
| Art Unit(s) | 1654, 1675 |
| Total Applications | 712 |
| Issued Applications | 367 |
| Pending Applications | 94 |
| Abandoned Applications | 262 |
Applications
| Application number | Title of the application | Filing Date | Status |
|---|---|---|---|
Array
(
[id] => 17687701
[patent_doc_number] => 20220194993
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2022-06-23
[patent_title] => FLAGELLIN FUSION PROTEIN AND USE THEREOF
[patent_app_type] => utility
[patent_app_number] => 17/605455
[patent_app_country] => US
[patent_app_date] => 2020-04-22
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 11691
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -22
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17605455
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/605455 | FLAGELLIN FUSION PROTEIN AND USE THEREOF | Apr 21, 2020 | Abandoned |
Array
(
[id] => 19676198
[patent_doc_number] => 12188049
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2025-01-07
[patent_title] => Methods for mobilizing stem cells
[patent_app_type] => utility
[patent_app_number] => 16/848065
[patent_app_country] => US
[patent_app_date] => 2020-04-14
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 7
[patent_figures_cnt] => 7
[patent_no_of_words] => 3544
[patent_no_of_claims] => 6
[patent_no_of_ind_claims] => 1
[patent_words_short_claim] => 42
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16848065
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/848065 | Methods for mobilizing stem cells | Apr 13, 2020 | Issued |
Array
(
[id] => 16190780
[patent_doc_number] => 20200231629
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2020-07-23
[patent_title] => BETA-HAIRPIN PEPTIDOMIMETICS
[patent_app_type] => utility
[patent_app_number] => 16/843527
[patent_app_country] => US
[patent_app_date] => 2020-04-08
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 22699
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -9
[patent_words_short_claim] => 633
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16843527
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/843527 | Beta-hairpin peptidomimetics | Apr 7, 2020 | Issued |
Array
(
[id] => 17655489
[patent_doc_number] => 20220175954
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2022-06-09
[patent_title] => HYPOXIA-INDUCING CRYOGELS
[patent_app_type] => utility
[patent_app_number] => 17/600198
[patent_app_country] => US
[patent_app_date] => 2020-04-02
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 8580
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -19
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17600198
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/600198 | HYPOXIA-INDUCING CRYOGELS | Apr 1, 2020 | Abandoned |
Array
(
[id] => 17627247
[patent_doc_number] => 20220162262
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2022-05-26
[patent_title] => NOVEL COMPOUNDS AND THERAPEUTIC USES THEREOF
[patent_app_type] => utility
[patent_app_number] => 17/594111
[patent_app_country] => US
[patent_app_date] => 2020-04-01
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 12971
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -19
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17594111
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/594111 | NOVEL COMPOUNDS AND THERAPEUTIC USES THEREOF | Mar 31, 2020 | Abandoned |
Array
(
[id] => 20158213
[patent_doc_number] => 12384825
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2025-08-12
[patent_title] => Monomeric peptide multi-agonist targeting the GLP1 receptor and NPY receptors
[patent_app_type] => utility
[patent_app_number] => 17/600221
[patent_app_country] => US
[patent_app_date] => 2020-04-01
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 16
[patent_figures_cnt] => 16
[patent_no_of_words] => 4506
[patent_no_of_claims] => 9
[patent_no_of_ind_claims] => 1
[patent_words_short_claim] => 14
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17600221
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/600221 | Monomeric peptide multi-agonist targeting the GLP1 receptor and NPY receptors | Mar 31, 2020 | Issued |
Array
(
[id] => 17655419
[patent_doc_number] => 20220175884
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2022-06-09
[patent_title] => MODULATION OF WNT SIGNALING IN AUDITORY DISORDERS
[patent_app_type] => utility
[patent_app_number] => 17/438806
[patent_app_country] => US
[patent_app_date] => 2020-04-01
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 19046
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -34
[patent_words_short_claim] => 21
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17438806
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/438806 | MODULATION OF WNT SIGNALING IN AUDITORY DISORDERS | Mar 31, 2020 | Abandoned |
Array
(
[id] => 16359460
[patent_doc_number] => 20200316211
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2020-10-08
[patent_title] => LOCALLY ACTING TOLL-LIKE RECEPTOR 7 (TLR7) AND/OR TLR8 AGONIST IMMUNOTHERAPY COMPOUNDS AND THEIR USES
[patent_app_type] => utility
[patent_app_number] => 16/837521
[patent_app_country] => US
[patent_app_date] => 2020-04-01
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 22587
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -17
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16837521
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/837521 | LOCALLY ACTING TOLL-LIKE RECEPTOR 7 (TLR7) AND/OR TLR8 AGONIST IMMUNOTHERAPY COMPOUNDS AND THEIR USES | Mar 31, 2020 | Abandoned |
Array
(
[id] => 17088698
[patent_doc_number] => 11116868
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2021-09-14
[patent_title] => Wound spray
[patent_app_type] => utility
[patent_app_number] => 16/835662
[patent_app_country] => US
[patent_app_date] => 2020-03-31
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 1
[patent_figures_cnt] => 1
[patent_no_of_words] => 8364
[patent_no_of_claims] => 15
[patent_no_of_ind_claims] => 2
[patent_words_short_claim] => 152
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16835662
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/835662 | Wound spray | Mar 30, 2020 | Issued |
Array
(
[id] => 16296115
[patent_doc_number] => 20200281838
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2020-09-10
[patent_title] => SKIN WHITENING PEPTIDE AGENTS
[patent_app_type] => utility
[patent_app_number] => 16/830572
[patent_app_country] => US
[patent_app_date] => 2020-03-26
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 9828
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -12
[patent_words_short_claim] => 105
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16830572
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/830572 | SKIN WHITENING PEPTIDE AGENTS | Mar 25, 2020 | Abandoned |
Array
(
[id] => 16297770
[patent_doc_number] => 20200283493
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2020-09-10
[patent_title] => Novel Insulin Derivatives and the Medical Uses Hereof
[patent_app_type] => utility
[patent_app_number] => 16/829769
[patent_app_country] => US
[patent_app_date] => 2020-03-25
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 25235
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -19
[patent_words_short_claim] => 197
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16829769
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/829769 | Novel Insulin Derivatives and the Medical Uses Hereof | Mar 24, 2020 | Abandoned |
Array
(
[id] => 17611940
[patent_doc_number] => 20220154219
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2022-05-19
[patent_title] => GENE DELIVERY PARTICLES TO INDUCE TUMOR-DERIVED ANTIGEN PRESENTING CELLS
[patent_app_type] => utility
[patent_app_number] => 17/441188
[patent_app_country] => US
[patent_app_date] => 2020-03-23
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 24677
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -26
[patent_words_short_claim] => 40
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17441188
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/441188 | GENE DELIVERY PARTICLES TO INDUCE TUMOR-DERIVED ANTIGEN PRESENTING CELLS | Mar 22, 2020 | Pending |
Array
(
[id] => 17611874
[patent_doc_number] => 20220154153
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2022-05-19
[patent_title] => NEW INHIBITORS OF LRRK2/PP1 INTERACTION
[patent_app_type] => utility
[patent_app_number] => 17/439641
[patent_app_country] => US
[patent_app_date] => 2020-03-21
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 13946
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -17
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17439641
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/439641 | NEW INHIBITORS OF LRRK2/PP1 INTERACTION | Mar 20, 2020 | Pending |
Array
(
[id] => 17593569
[patent_doc_number] => 20220143142
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2022-05-12
[patent_title] => DIRECT REPROGRAMMING OF CARDIAC FIBROBLASTS INTO CARDIOMYOCYTES USING AN ENDOTHELIAL CELL TRANSDIFFERENTIATION STRATEGY
[patent_app_type] => utility
[patent_app_number] => 17/593286
[patent_app_country] => US
[patent_app_date] => 2020-03-17
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 14655
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -130
[patent_words_short_claim] => 33
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17593286
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/593286 | DIRECT REPROGRAMMING OF CARDIAC FIBROBLASTS INTO CARDIOMYOCYTES USING AN ENDOTHELIAL CELL TRANSDIFFERENTIATION STRATEGY | Mar 16, 2020 | Pending |
Array
(
[id] => 17640653
[patent_doc_number] => 20220168391
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2022-06-02
[patent_title] => USE OF EPIDERMAL GROWTH FACTOR IN DIABETIC FOOT ULCER TREATMENT
[patent_app_type] => utility
[patent_app_number] => 17/440698
[patent_app_country] => US
[patent_app_date] => 2020-03-16
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 5642
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -5
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17440698
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/440698 | USE OF EPIDERMAL GROWTH FACTOR IN DIABETIC FOOT ULCER TREATMENT | Mar 15, 2020 | Abandoned |
Array
(
[id] => 17595707
[patent_doc_number] => 20220145281
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2022-05-12
[patent_title] => NEW VACCINAL STRATEGY TO PREVENT OR TREAT RHUMATOID ARTHRITIS
[patent_app_type] => utility
[patent_app_number] => 17/435267
[patent_app_country] => US
[patent_app_date] => 2020-03-06
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 10288
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -12
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17435267
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/435267 | NEW VACCINAL STRATEGY TO PREVENT OR TREAT RHUMATOID ARTHRITIS | Mar 5, 2020 | Pending |
Array
(
[id] => 17657056
[patent_doc_number] => 20220177521
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2022-06-09
[patent_title] => PROCESS FOR THE PREPARATION OF DEGARELIX
[patent_app_type] => utility
[patent_app_number] => 17/437019
[patent_app_country] => US
[patent_app_date] => 2020-03-05
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 7272
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -18
[patent_words_short_claim] => 21
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17437019
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/437019 | PROCESS FOR THE PREPARATION OF DEGARELIX | Mar 4, 2020 | Pending |
Array
(
[id] => 20577305
[patent_doc_number] => 12569540
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2026-03-10
[patent_title] => Human recombinant hyposialylated erythropoietin, methods of purification and therapeutic uses thereof
[patent_app_type] => utility
[patent_app_number] => 17/640133
[patent_app_country] => US
[patent_app_date] => 2020-02-19
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 9
[patent_figures_cnt] => 17
[patent_no_of_words] => 2816
[patent_no_of_claims] => 6
[patent_no_of_ind_claims] => 1
[patent_words_short_claim] => 88
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17640133
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/640133 | Human recombinant hyposialylated erythropoietin, methods of purification and therapeutic uses thereof | Feb 18, 2020 | Issued |
Array
(
[id] => 16236817
[patent_doc_number] => 20200254051
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2020-08-13
[patent_title] => COMBINATION THERAPY WITH PEPTIDE EPOXYKETONES
[patent_app_type] => utility
[patent_app_number] => 16/791379
[patent_app_country] => US
[patent_app_date] => 2020-02-14
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 16911
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -10
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16791379
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/791379 | COMBINATION THERAPY WITH PEPTIDE EPOXYKETONES | Feb 13, 2020 | Abandoned |
Array
(
[id] => 16236870
[patent_doc_number] => 20200254104
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2020-08-13
[patent_title] => METHODS OF MAKING AND USING PHYTOCANNABINOIDS COMPLEXED WITH A PROTEIN, PEPTIDE, AMINO ACID, POLYSACCHARIDE, DISACCHRIDE, OR MONOSACCHARIDE
[patent_app_type] => utility
[patent_app_number] => 16/787460
[patent_app_country] => US
[patent_app_date] => 2020-02-11
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 8242
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -19
[patent_words_short_claim] => 25
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16787460
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/787460 | METHODS OF MAKING AND USING PHYTOCANNABINOIDS COMPLEXED WITH A PROTEIN, PEPTIDE, AMINO ACID, POLYSACCHARIDE, DISACCHRIDE, OR MONOSACCHARIDE | Feb 10, 2020 | Pending |